Literature DB >> 22575857

Infantile hemangioma: clinical assessment of the involuting phase and implications for management.

Rafael A Couto1, Reid A Maclellan, David Zurakowski, Arin K Greene.   

Abstract

BACKGROUND: Infantile hemangioma involutes during childhood; the tumor decreases in size and its color fades. Reconstructive procedures are often withheld until the lesion stops improving. The purpose of this study was to determine the age at which involution of infantile hemangioma ends, and factors that influence its regression.
METHODS: Consecutive patients with infantile hemangioma managed between 2007 and 2011 were studied retrospectively. The outcome variable was age at which the appearance of the infantile hemangioma ceased to improve. Predictive variables were sex, lesion size, location, tumor depth, ulceration, and history of treatment (local or systemic corticosteroid).
RESULTS: The study comprised 81 patients. Infantile hemangioma was located on the head/neck (79.0 percent), trunk (13.6 percent), or extremity (7.4 percent). Average tumor area was 9.3 ± 9.7 cm. Twenty-six percent of the cohort was treated with a corticosteroid during the proliferative phase and 87.6 percent underwent reconstruction for a residual deformity. Kaplan-Meier analysis estimated that involution ceased at a median age of 36 months (interquartile range, 30 to 42 months), and 92 percent of tumors completed involution by 48 months. Multivariate Cox proportional hazards regression model showed that sex (p = 0.80), lesion size (p = 0.09), location (p = 0.77), tumor depth (p = 0.74), ulceration (p = 0.18), and previous local (p = 0.73) or systemic (p = 0.60) corticosteroid treatment did not influence regression.
CONCLUSIONS: Most infantile hemangiomas do not improve significantly after 3.5 years of age. Reconstructive procedures should be considered at this age; the tumor has been allowed to regress and the deformity is improved before the development of long-term memory and psychosocial morbidity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575857     DOI: 10.1097/PRS.0b013e31825dc129

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  22 in total

1.  [Vascular anomalies. Part I: vascular tumors].

Authors:  S Mylonas; S Brunkwall; J Brunkwall
Journal:  Chirurg       Date:  2018-03       Impact factor: 0.955

2.  Analysis of Follicle-Stimulating Hormone Receptor in Infantile Hemangioma.

Authors:  Reid A Maclellan; Dennis J Konczyk; Jeremy A Goss; Arin K Greene
Journal:  Ann Plast Surg       Date:  2018-04       Impact factor: 1.539

3.  A retrospective study to classify surgical indications for infantile hemangiomas.

Authors:  Andrew H Y Lee; Krista L Hardy; David Goltsman; Peter Liou; Maria C Garzon; Christine H Rohde; June K Wu
Journal:  J Plast Reconstr Aesthet Surg       Date:  2014-05-16       Impact factor: 2.740

4.  A hydrogel-endothelial cell implant mimics infantile hemangioma: modulation by survivin and the Hippo pathway.

Authors:  Masayuki Tsuneki; Steven Hardee; Michael Michaud; Raffaella Morotti; Erin Lavik; Joseph A Madri
Journal:  Lab Invest       Date:  2015-05-11       Impact factor: 5.662

5.  How to Manage Disfiguring Scars in Involuted Infantile Hemangioma.

Authors:  Shunsuke Yuzuriha; Fumio Nagai; Masahiko Noguchi
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-06-06       Impact factor: 4.730

6.  One Possible Mechanism of Pulsed Dye Laser Treatment on Infantile Hemangioma: Induction of Endothelial Apoptosis and Serum vascular endothelial growth factor (VEGF) Level Changes.

Authors:  Yongqian Cao; Fagang Wang; Qingwei Jia; Rongjian Xu; Wei Dang; Qing Chen; Li Lin; Yibing Wang
Journal:  J Lasers Med Sci       Date:  2014

Review 7.  Beta blockers: an innovation in the treatment of infantile hemangiomas.

Authors:  Shehla Admani; Stephanie Feldstein; Ernesto M Gonzalez; Sheila Fallon Friedlander
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

8.  Serum Basic Fibroblastic Growth Factor Levels in Children with Infantile Hemangioma.

Authors:  Hikmet Gulsah Tanyildiz; Emel Cabi Unal; Hafize Gokce; Gulsan Yavuz; Nurdan Tacyildiz; Handan Dincaslan; Ceyda Gurman; Zeynep Biyikli
Journal:  Indian J Pediatr       Date:  2016-01-27       Impact factor: 1.967

Review 9.  The impact of pediatric skin disease on self-esteem.

Authors:  K L Vivar; L Kruse
Journal:  Int J Womens Dermatol       Date:  2017-12-12

10.  The effectiveness of oral propranolol for infantile hemangioma on the head and neck region: A case series.

Authors:  Prasetyanugraheni Kreshanti; Nandya Titania Putri; Valencia Jane Martin; Chaula Luthfia Sukasah
Journal:  Int J Surg Case Rep       Date:  2021-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.